Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

Found (177) clinical trials

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

The purpose of this study is to evaluate the efficacy of ontamalimab as maintenance therapy treatment of remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

Phase

5.6 miles

Learn More »

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Phase

5.6 miles

Learn More »

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.

Phase

5.6 miles

Learn More »

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

This study will investigate a Clostridium difficile vaccine in healthy adults 50 years of age and older. In half the healthy adults, all 3 doses given are the Clostridium difficile vaccine, and in half the healthy adults, 2 of the 3 doses are the Clostridium difficile vaccine with the other …

Phase

5.6 miles

Learn More »

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).

Phase

5.6 miles

Learn More »

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Subjects will be randomized to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome at Week 52 will be Total Improvement Score (TIS), which is a weighted composite measure of improvement from baseline …

Phase

5.6 miles

Learn More »

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)

Phase

5.6 miles

Learn More »

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Approximately 350 adult subjects will be recruited from approximately 80 study centers in the United States, Canada, and Europe who were enrolled in the ASPEN-1 Study Protocol 1720302 and de novo subjects (not previously enrolled in ASPEN-1 Study Protocol 1720302) will be treated with up to 4 different doses of …

Phase

5.6 miles

Learn More »

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

We are currently monitoring enrollment and the impacts on the study due to COVID-19. We plan to update this posting with a revised Primary Completion Date and Study Completion Date that reflect the anticipated operational study timeline combined with COVID-19 impacts when we have more clarity.

Phase

5.6 miles

Learn More »

It is a year long study with 12 visits into the study office. Stipend will be received for your participation. Patient Inclusion Criteria: Must be taking either Celebrex or Naproxen to qualify. Patient Exclusion Criteria: Cannot have Rheumatoid arthritis. No cancer. Cannot have body mass index over 39.

Phase

5.6 miles

Learn More »